Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that President and CEO Nader Pourhassan, Ph.D., and Chief Medical Officer Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., will host an investment community conference call on Wednesday, December 12, at 4:00 p.m. ET. To access the call, interested parties should dial 877-407-2986 (U.S. and Canada) or 201-378-4916 (international). A live audio webcast of the call may also be accessed via CytoDyn’s corporate website at www.CytoDyn.com under the Investors section, and it will be archived for 60 days following the conclusion of the call. Web participants are encouraged to visit the website 15 minutes prior to the start of the call to register and download and install any necessary software. For those unable to attend, a replay of the conference call will be available until February 12, 2019. Interested parties should dial 877-660-6853 (U.S. and Canada) or 201-612-7415 (international) and enter conference identification number 13683202 to access this replay.
To view the full press release, visit http://ibn.fm/taAjr
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.